SCHEMBL1705948

SCHEMBL1705948

CCc1cncc2ccc(O)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.46
ESR2 Q92731 5/20 0.46
ESRRB O95718 1/20 0.46
ESRRA P11474 1/20 0.46
CYP17A1 P05093 6/20 0.43
CYP3A4 P08684 6/20 0.43
CYP11B1 P15538 6/20 0.43
CYP11B2 P19099 6/20 0.43
PDE10A Q9Y233 2/20 0.41
MTNR1A P48039 1/20 0.40
MTNR1B P49286 1/20 0.40
HSD17B3 P37058 1/20 0.39
HSD17B1 P14061 1/20 0.39
ERN1 O75460 1/20 0.37
IKBKB O14920 1/20 0.36
JAK2 O60674 1/20 0.36
ROCK2 O75116 1/20 0.36
JAK1 P23458 1/20 0.36
TYK2 P29597 1/20 0.36
JAK3 P52333 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL4812125 0.80 ALDH1A1 (0.48) CYP17A1CYP3A4CYP11B1CYP11B2MTNR1A
SCHEMBL3052255 0.80 EGFR (0.42) PDE10AIKBKBJAK2ROCK2JAK1
SCHEMBL20429324 0.80 PDE10A (0.43) PDE10AIKBKBJAK2ROCK2JAK1
SCHEMBL1705752 0.76 PDE10A (0.55) CYP17A1CYP3A4CYP11B1CYP11B2PDE10A
SCHEMBL28986981 0.75 CYP11B1 (0.49) ESR1ESR2CYP17A1CYP3A4CYP11B1
SCHEMBL2500489 0.74 CYP17A1 (0.38) ESR1ESR2CYP17A1CYP3A4CYP11B1
SCHEMBL4730778 0.74 KDM4E (0.46) CYP3A4IKBKBJAK2ROCK2JAK1
SCHEMBL3960876 0.74 MTNR1A (0.60) ESR1ESR2ESRRBESRRAMTNR1A
SCHEMBL873335 0.73 CYP11B1 (0.47) CYP17A1CYP3A4CYP11B1CYP11B2PDE10A
SCHEMBL19383227 0.73 PDE10A (0.48) CYP11B1CYP11B2PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8710228-B2 Cycloalkylamine substituted isoquinoline derivatives SANOFI (FR) 2014-04-29 US disclosed
US-8710228-B2 Cycloalkylamine substituted isoquinoline derivatives SANOFI (FR) 2014-04-29 US disclosed
US-8710228-B2 Cycloalkylamine substituted isoquinoline derivatives SANOFI (FR) 2014-04-29 US disclosed
EP-2125746-B1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE DERIVATIVES SANOFI SA (FR) 2012-04-18 EP disclosed
EP-2125746-B1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE DERIVATIVES SANOFI SA (FR) 2012-04-18 EP disclosed
US-20100081671-A1 Cycloalkylamine substituted isoquinoline derivatives SANOFI-AVENTIS (FR) 2010-04-01 US disclosed
US-20100081671-A1 Cycloalkylamine substituted isoquinoline derivatives SANOFI-AVENTIS (FR) 2010-04-01 US disclosed
US-20100081671-A1 Cycloalkylamine substituted isoquinoline derivatives SANOFI-AVENTIS (FR) 2010-04-01 US disclosed
EP-2125746-A1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE DERIVATIVES Sanofi-Aventis (FR) 2009-12-02 EP disclosed
WO-2008077554-A1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE DERIVATIVES SANOFI-AVENTIS (FR) 2008-07-03 WO disclosed
WO-2008077554-A1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE DERIVATIVES SANOFI-AVENTIS (FR) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081671-A1 Cycloalkylamine substituted isoquinoline derivatives MYLK2, MYLK, MYLK3 ESR1 4825/4885ESR2 3731/4885ESRRB 2830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.